Response's troponin I and CK-MB POC heart tests:
This article was originally published in Clinica
Executive Summary
Response Biomedical has received market clearance from Health Canada's Therapeutic Products Directorate to add two additional cardiac marker tests to its fluorescence-based, POC RAMP reader. The tests, for troponin I and CK-MB, are designed to help speed up heart attack diagnosis. The Vancouver, British Columbia firm has already gained Canadian approval to test for a third cardiac marker - myoglobin - on the RAMP reader and for the general clinical use of reader. The Reader and all three cardiac marker tests are already approved in the US, where, according to Response, the market for POC cardiac marker tests in 2004 is estimated to be around $150m.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.